eprintid: 10042361
rev_number: 25
eprint_status: archive
userid: 608
dir: disk0/10/04/23/61
datestamp: 2018-02-02 10:51:06
lastmod: 2022-01-24 01:57:44
status_changed: 2018-02-02 10:51:06
type: article
metadata_visibility: show
creators_name: Saracino, A
creators_name: Cozzi-Lepri, A
creators_name: Shanyinde, M
creators_name: Ceccherini Silberstein, F
creators_name: Nozza, S
creators_name: Di Biagio, A
creators_name: Cassola, G
creators_name: Bruno, G
creators_name: Capobianchi, M
creators_name: Puoti, M
creators_name: Monno, L
creators_name: d'Arminio Monforte, A
creators_name: ICONA Foundation Study, 
title: HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients
ispublished: pub
divisions: UCL
divisions: B02
divisions: D01
divisions: G16
note: : © 2018 Saracino et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
abstract: BACKGROUND: In vitro, gp120 of both X4 and R5 HIV-1 strains activates human hepatic stellate cells, but if it can promote liver fibrosis in vivo is unknown. We aimed to evaluate if patients carrying X4 or R5 strains have a different liver fibrosis (LF) progression over time. METHODS: A total of 1,137 HIV-infected patients in ICONA cohort (21% females, 7% HCV co-infected) with an available determination of HIV-1 co-receptor tropism (CRT), a Fibrosis-4 Index for Liver Fibrosis (FIB-4) <3.25 and at least one-year follow-up were included. CRT was assessed by gp120 sequencing on plasma RNA and geno2pheno algorithm (10% false positive rate) or by Trofile. LF was assessed by means of FIB-4. LF progression was defined as an absolute score increase or a transition to higher fibrosis stratum and/or occurrence of liver-related clinical events. RESULTS: A total of 249 (22%) patients carried X4 strains, which were associated with older age, lower CD4 count, lower nadir CD4, and intravenous drug use. Overall, X4 and R5 patients had similar baseline FIB-4 scores and similar mean FIB-4 slope after a median follow-up of 35 months. There was no difference between X4 and R5 for time to LF progression (p = 0.925). Estimated risk of LF at 24 months (95% CI) after baseline in X4 and R5 was 10.6% (8.3-12.9) and 9.9% (5.9-14.0), respectively. Age, HCV co-infection, diabetes, HIV-duration, HIV-RNA>100.000 cp/mL, antiretroviral therapy exposure were associated with LF progression at multivariate analysis. CONCLUSIONS: A slight LF progression over time was observed in HIV-infected patients. No difference was demonstrated for X4 and R5 HIV-1 strains in accelerating LF evolution.
date: 2018
date_type: published
official_url: http://dx.doi.org/10.1371/journal.pone.0190302
oa_status: green
full_text_type: pub
pmcid: PMC5764264
language: eng
primo: open
primo_central: open_green
article_type_text: Journal Article
verified: verified_manual
elements_id: 1528132
doi: 10.1371/journal.pone.0190302
pii: PONE-D-17-29533
lyricists_name: Cozzi-Lepri, Alessandro
lyricists_id: ACOZZ70
actors_name: Laslett, David
actors_id: DLASL34
actors_role: owner
full_text_status: public
publication: PLoS One
volume: 13
number: 1
article_number: e0190302
event_location: United States
issn: 1932-6203
citation:        Saracino, A;    Cozzi-Lepri, A;    Shanyinde, M;    Ceccherini Silberstein, F;    Nozza, S;    Di Biagio, A;    Cassola, G;                         ... ICONA Foundation Study; + view all <#>        Saracino, A;  Cozzi-Lepri, A;  Shanyinde, M;  Ceccherini Silberstein, F;  Nozza, S;  Di Biagio, A;  Cassola, G;  Bruno, G;  Capobianchi, M;  Puoti, M;  Monno, L;  d'Arminio Monforte, A;  ICONA Foundation Study;   - view fewer <#>    (2018)    HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients.                   PLoS One , 13  (1)    , Article e0190302.  10.1371/journal.pone.0190302 <https://doi.org/10.1371/journal.pone.0190302>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10042361/1/journal.pone.0190302.pdf